Sellas Life Sciences (SLS) rises 5% as retail traders debate buyout scenarios
Sellas Life Sciences shares rose 5% to $10.49 on Monday, as retail investors on Stocktwits discussed buyout ideas after the CEO's anniversary post.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to Stocktwits, shares of Sellas Life Sciences gained 5% on Monday to $10.49, ending a three-session losing streak. The move followed a LinkedIn post from CEO Angelos Stergiou, who marked the company's 15th anniversary and described the next phase as a focus on its investigational cancer treatments GPS and SLS009.
Retail sentiment on the platform cooled from bullish to bearish a day earlier, even as message volume jumped 258% over 24 hours. Some users floated buyout valuations ranging from $40 billion to $120 billion, and bullish price targets ran from $100 to above $540.
The company's two lead programs are still pending. The Phase 3 Regal trial of GPS in acute myeloid leukemia is awaiting 80 deaths to trigger final analysis, with 78 events reported as of May 11. Sellas also expects fourth-quarter topline data from its Phase 2 SLS009 study in newly diagnosed AML.
why it matters
The stock is up 178% year to date, so the rally rests largely on speculation. The company has not confirmed buyout talk, and the valuations cited by retail users are not drawn from its disclosures. For a small biotech, trial readouts remain the main catalysts to watch.
tags
instruments
sources
- SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years — Stocktwits, 20 October 2026 at 04:07 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗